J9227 Injection. isatuximab-irfc 10 milligrams
Also known as: isatuximab, Sarclisa
Intravenous injection of isatuximab-irfc, a monoclonal antibody targeting CD38, dosed per 10 milligrams.
In Plain Language
multiple myeloma-targeting antibody; immune-boosting cancer therapy
Clinical Context
Used for relapsed or refractory multiple myeloma in combination with pomalidomide and dexamethasone.
RVU Information
CPT J9227 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9227?
CPT J9227 (Injection. isatuximab-irfc 10 milligrams) is a J Codes (Drugs) code. Intravenous injection of isatuximab-irfc, a monoclonal antibody targeting CD38, dosed per 10 milligrams.
How is J9227 administered?
CPT J9227 is administered by a healthcare provider, typically via injection or infusion. Used for relapsed or refractory multiple myeloma in combination with pomalidomide and dexamethasone. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9227 used?
Used for relapsed or refractory multiple myeloma in combination with pomalidomide and dexamethasone.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.